


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of inducing an insulin sensitizing or insulin mimetic effect in a tissue of a patient, the method comprising administering to the patient ~~Use of a~~ compound chosen from the group constituted by mono-hydroxylated amino acids, poly-hydroxylated amino acids, and the lactonic forms of these acids, ~~for the manufacture of a medicament with insulin mimetic and/or insulin sensitizing effects.~~

2. (Currently Amended) The method of ~~Use according to~~ claim 1, characterised in that said compound exercises ~~medicament is intended to exercise~~ an insulin mimetic and/or insulin-sensitizing effect at the level of ~~the~~ a peripheral target tissue ~~tissues~~ of insulin.

3. (Currently Amended) The method of ~~Use according to~~ claim 1, characterised in that said compound reduces phosphatase activity associated with the signaling route of the insulin receptor, and/or stimulates PI 3-kinase activity on IRS-1 and/or IRS-2.

4. (Currently Amended) The method of ~~Use according to~~ claim 1, characterised in that said compound is 4-hydroxyisoleucine of formula



and/or the lactonic form of this amino acid.

5. (Currently Amended) The method of ~~Use according to~~ claim 4, characterised in that the 4-hydroxyisoleucine is presented in the form of its 2S, 3R, 4S isomer or the corresponding lactone.

6. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament intended for the treatment of~~ wherein the patient has insulin resistance.

7. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament intended to combat the~~ wherein the patient has or is at risk of developing one or more of the syndromes associated with insulin resistance.

8. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament against~~ wherein the patient has or is at risk of developing hyperinsulinemia.

9. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament against~~ wherein the patient has or is at risk of developing insulin resistance associated with ageing.

10. (Currently Amended) ~~The method Use of claim 1, for the manufacture of a medicament against~~ wherein the patient has or is at risk of developing one or more of the illnesses associated with obesity.

11. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament intended to inhibit the proliferation of cell lines associated with the risk of the appearance of~~ wherein the patient has or is at risk of developing cancer.

12. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament intended for the prevention of~~ wherein the patient is at risk of developing insulin resistance.

13. (Currently Amended) ~~The method of Use according to claim 1, for the manufacture of a medicament intended to reduce~~ wherein administration of the compound reduces the need of the patient for exogenic insulin.

14. (Original) Pharmaceutical composition or kit comprising both insulin and a compound chosen from the group constituted by mono-hydroxylated amino acids, poly-hydroxylated amino acids, and the lactonic forms of these acids.